antibody

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2, TREM-2, Triggering Receptor Expressed on Monocytes 2)

T8282-12B

100 ug

polyclonal

domestic goat

nonconjugated

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2, TREM-2, Triggering Receptor Expressed on Monocytes 2)

goat

Pab

Antibodies

100 ug

IgG

TREM-2 (Triggering Receptor Expressed by Myeloid cells) is an Ig superfamily cell surface receptor that activates a number of myeloid cell types. It is a member of a small gene family located on human chromosome 6p21 and mouse chromosome 17 in a region linked to the MHC. A single human TREM-2 gene has been described, however, two closely related orthologs were reported in mouse. The proteins differ by only 3aa and were designated TREM-2a and TREM-2b. TREM-2 is type I transmembrane protein consisting of a single extracellular immunoglobulin (V-like) domain, a transmembrane domain with a positively charged lysine residue, and a short cytoplasmic tail. It associates with the signal adapter protein, DAP12, for signaling and function. DAP12 has a cytoplasmic ITAM that is phosphorylated upon ligand binding leading to the subsequent activation of cytoplasmic tyrosine kinases. TREM-2 is expressed by immature monocyte-derived dendritic cells (DC), and expression is down-regulated upon activation of DC by microbial products and costimulatory signals. Ligation of TREM-2 on immature DC with anti-TREM-2 antibodies results in partial DC activation and the up-regulation of CCR7 and some co-stimulatory molecules. A role for TREM-2 in the functioning of osteoclasts and microglia is suggested by the discovery that homozygous loss-of-function mutations in either TREM-2 or DAP12 result in Nasu-Hakola disease characterized by a combination of presenile demetia and bone cysts. In vitro studies indicate that the differentiation of myeloid precursors into osteoclasts is dramatically impaired in TREM-2 deficient individuals. Applications: Suitable for use in ELISA and Immunohistochemistry. Other applications not tested. Recommended Dilution: ELISA: 1:32,000 Immunohistochemistry (Paraffin): 2-3ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu

Synthetic peptide corresponding to C-HGQKPGTHPPSELD, from human TREM2, at C-terminal (NP_061838.1).

Recognizes human TREM2.

Purified by immunoaffinity chromatography

Supplied as a liquid in Tris saline, 0.02% sodium azide, pH 7.3, 0.5% BSA.

~0.5mg/ml

Product Type: Pab Host: goat Source: human Concentration: ~0.5mg/ml Form: Supplied as a liquid in Tris saline, 0.02% sodium azide, pH 7.3, 0.5% BSA. Purity: Purified by immunoaffinity chromatography. Immunogen: Synthetic peptide corresponding to C-HGQKPGTHPPSELD, from human TREM2, at C-terminal (NP_061838.1). Specificity: Recognizes human TREM2. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

E IHC

-20°C

1. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007 Apr;4(4):e124.

https://usbio-images.r.worldssl.net/prodimages/27/T8282-12B_1.jpg